Vera Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
VERA$30.61+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Trading Arrangements
During the quarter ended December 31, 2023, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act adopted or terminated the contracts, instructions or written plans for the purchase or sale of the Company’s securities set forth in the table below.
| Type of Trading Arrangement | ||||||
| Name and Position | Action | Adoption/ TerminationDate | Rule 10b5-1* | Non-Rule 10b5-1** | Total Shares of Class A Common Stock to be Sold | Expiration Date |
|---|---|---|---|---|---|---|
| Celia Lin, Chief Medical Officer*** | Adoption | October 10, 2023 | X | Up to 134,401 | December 19, 2024**** | |
| * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | ||||||
| ** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. | ||||||
| ***Dr. Lin separated from Vera effective January 3, 2024. | ||||||
| ****In connection with her separation from Vera, Dr. Lin terminated this 10b5-1 Plan effective January 19, 2024. | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.